Columnist Shalom Lin and his partner, Amanda — both disabled artists — find that their challenges are exactly what can drive ...

Enrollment is now ongoing in a first-in-human clinical trial testing EPI-321, a therapy designed to target the underlying ...

A mouse model study of Precision BioSciences’ gene-editing therapy PBGENE-DMD found it produced long-term functional ...

The FDA has granted breakthrough therapy designation to DYNE-251 for the treatment of DMD in patients amenable to exon 51 ...

Sarepta will soon resume shipping Elevidys for ambulatory Duchenne muscular dystrophy patients after a review of safety data ...

Columnist Betty Vertin, whose days often feel overloaded, describes how it feels when her life as a caregiver is recognized and affirmed.

Share this article: An experimental gene editing therapy for Duchenne muscular dystrophy (DMD) being developed by Precision Biosciences has received orphan drug status from the U.S. Food and Drug ...

Elevidys (delandistrogene moxeparvovec-rokl), previously called SRP-9001, is a onetime gene therapy approved for certain patients with DMD.

Marisa Wexler is a senior science writer for Muscular Dystrophy News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of muscular dystrophy ...

The Phase 3 trial EMBARK failed to meet its main goal but the gene therapy Elevidys led to improvements in some measures in boys with DMD.

The FDA has given fast-track designation to Avidity Biosciences' AOC 1020, a therapy candidate for facioscapulohumeral muscular dystrophy.